PMPeptide Methodology
RESEARCH METHODOLOGY

Peptide Methodology

Research peptide protocols, reconstitution, and analytical methods.

USP <71> Sterility Testing for Reconstitution Diluents — What the Spec Requires

2026-06-04 · Peptide Methodology Editorial

USP General Chapter <71> recognizes two sterility test methods for compounded, injectable, and reconstitution-grade preparations: membrane filtration and direct inoculation. For aqueous diluents — sterile water for injection, bacteriostatic water, 0.9% saline — filtration is the default. Direct inoculation carries a real risk: preservative carry-over can inhibit the very test organisms the assay is meant to detect, which produces false negatives. Filter the preservative out first, and that problem goes away.

The numbers are fixed. Test articles run against two media:

Incubation runs at least 14 days. No growth in either medium, or the lot fails — there is no partial pass. One step has to come first, though: method suitability testing. That confirms the diluent itself doesn't suppress organism growth, and the suitability data belongs on the certificate of analysis alongside the result. Skip it in practice at your peril; a "clean" plate from an inhibitory matrix tells you nothing.

What a per-lot CoA should document

A research-grade diluent CoA built on USP <71> should specify, at minimum:

  1. Lot number and manufacture date
  2. Test method used (membrane filtration vs direct inoculation)
  3. Both media tested (FTM and SCDM), with explicit time and temperature
  4. Result: pass / no growth observed at day 14
  5. Method suitability confirmation (the lot did not interfere with the positive controls)
  6. Endotoxin testing per USP <85> (LAL or recombinant Factor C) reported in EU/mL — typically required to be below 0.5 EU/mL for parenteral use, ideally an order of magnitude lower for sensitive reconstitution research
  7. Bacteriostat content (e.g. 0.9% benzyl alcohol) if the product is bacteriostatic rather than purely sterile

Missing any of these, and the document is a marketing claim. Not an analytical record.

Why this matters for peptide reconstitution

A reconstituted peptide solution sits in a multi-dose vial for up to 28 days under refrigeration. Do the arithmetic: any contamination present in the diluent at reconstitution time has weeks to multiply before the last dose is drawn. That turns a sterility gap into a slow-burn problem you won't see until it's downstream of everything.

A diluent that was never independently sterility-tested adds a confounding variable to every result derived from that vial. In regulated research contexts it also undermines documentary chain-of-custody — the paper trail breaks at the one component nobody verified.

Several US-based suppliers publish per-lot CoAs documenting USP <71> testing for their bacteriostatic water products. Examples include BAC Water Depot and the legacy Hospira / Pfizer line through institutional distributors. Check that the lot number on the vial matches the one on the digital certificate. A document that's generic across lots is not a per-lot CoA, whatever the header says.

What to ignore

"USP grade," "pharmaceutical grade," "research grade" — none of these mean anything without an underlying CoA. Unverifiable on their own. The chapter citation is no substitute either. "Compliant with USP <71>" describes a process; the analytical record is what proves the process happened.

Further reading